In a similar study targeting Cep290, Maeder and coworkers used a single AAV5 vector to deliver a CRISPR-SaCas9 system for the treatment of LCA10 disorder as a proof-of-concept (Maeder et al., 2019). This evidence concerns the gene CEP290 and Leber congenital amaurosis 10.